Clinical Scorecard: Post-Prostate Biopsy Outcomes: Infection Risks, Preventive Measures, and Antimicrobial Management Based on a Global Study from 2010 to 2019

At a Glance

Key Highlights

• Symptomatic infectious complication rates after transrectal prostate biopsy vary from 1.9% to 27.7%, with an increasing trend over time.
• Comorbidities and older age are significant risk factors for post-biopsy infections.
• Antimicrobial resistance among common uropathogens contributes to failure of antibiotic prophylaxis, emphasizing the need for site-specific antimicrobial stewardship.

Guideline-Based Recommendations

Diagnosis

• Classify infectious complications severity according to CDC criteria aligned with EAU guidelines.
• Monitor for lower UTI symptoms (frequency, dysuria, urgency, prostate pain) and severe/systemic UTI symptoms (loin pain, rigour, fever) up to 2 weeks post-biopsy.

Management

• Administer antibiotic prophylaxis tailored to local antimicrobial resistance patterns.
• Consider patient history including prior antibiotic use, urinary tract infections, and comorbidities when planning prophylaxis.
• Hospital readmission and antibiotic treatment are indicators of severe infectious complications requiring prompt management.

Monitoring & Follow-up

• Follow patients for 2 weeks post-biopsy to assess for symptoms and microbiological outcomes.
• Perform preoperative urine cultures and post-biopsy urine cultures if infection is suspected.
• Track antimicrobial treatment effectiveness and adjust stewardship programs accordingly.

Risks

• Increased risk of infection with older age and presence of comorbidities.
• Rising antimicrobial resistance leading to prophylaxis failure.
• Hospital readmission due to infectious complications post-biopsy.

Patient & Prescribing Data

Men undergoing prostate biopsy, including repeat biopsies (19% of cases), median age 66 years

Antibiotic prophylaxis is commonly used but its effectiveness is challenged by antimicrobial resistance; stewardship programs are critical to optimize antibiotic use and reduce infection rates.

Clinical Best Practices

• Use site-specific antimicrobial stewardship programs to guide prophylactic antibiotic selection.
• Assess patient risk factors such as age, comorbidities, and prior antibiotic exposure before biopsy.
• Monitor patients closely for up to 2 weeks post-biopsy for early detection and treatment of infectious complications.
• Collect and analyze microbiological data pre- and post-biopsy to inform treatment decisions.
• Adhere to standardized criteria (CDC and EAU) for classification and management of infectious complications.

References

• European Association of Urology Guidelines on Urological Infections
• Global Prevalence Study of Infections in Urology (GPIU)
• Borghesi et al. Systematic Review on Infectious Complications Post-Prostate Biopsy